In the MAINTAIN phase II trial, an HR+/HER2− relapsed breast cancer population progressing during ET plus CDK4/6i changed the ET (to fulvestrant or exemestane) and were randomly allocated to treatment with ribociclib or a placebo. Here, CDK4 is linked to breast cancer.